Skip to main content
    V

    Voyager Therapeutics Inc (VYGR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.63
    -0.10 (-5.78%)

    Market Cap: $107.66M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Voyager Therapeutics Inc (VYGR) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Voyager Therapeutics (VYGR) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Voyager Therapeutics reported EPS of -$0.40, above the -$0.41 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    +28.43%
    Streak
    5 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.42
    Range-$0.88 - -$0.08
    13 analysts
    Revenue Consensus
    $8.43M
    Range$2.94M - $29.93M
    13 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.40
    Range-$0.52 - -$0.26
    5 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.41+2.8%
    60d ago-$0.38-4.8%
    30d ago-$0.38-4.8%
    7d ago-$0.38-4.8%
    Current-$0.40
    Revenue Consensus
    $5.62M
    Range$2.50M - $11.80M
    4 analysts

    Next Report

    VYGR has an expected report date of Mar 8, 2027.

    VYGR Earnings Call

    The latest VYGR earnings call transcript on file is labeled 2024Q4.

    Read the 2024Q4 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, VYGR beat 25 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $4.01M, down 70.0% from $13.37M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.40-$0.41-$0.80 - -$0.28+2.44%BeatN/A103 up, 0 downNov 5, 2026$4.01M
    Jun 30, 2026-$0.40-$0.55-$0.72 - -$0.40+27.27%BeatN/A91 up, 0 downAug 6, 2026$3.17M
    Mar 31, 2026-$0.47-$0.53-$0.63 - -$0.28+11.32%BeatN/A93 up, 3 downMay 7, 2026$2.59M
    Dec 31, 2025-$0.47-$0.51-$0.72 - -$0.33+7.93%BeatN/A112 up, 7 downMar 9, 2026$15.34M
    Sep 30, 2025-$0.47-$0.52-$0.60 - -$0.32+9.62%BeatN/A104 up, 4 downNov 10, 2025$13.37M
    Jun 30, 2025-$0.57-$0.52-$0.80 - -$0.31-9.62%MissN/A111 up, 2 downAug 6, 2025$5.20M
    Mar 31, 2025-$0.53-$0.44-$0.64 - -$0.17-20.45%MissN/A104 up, 2 downMay 6, 2025$6.47M
    Dec 31, 2024-$0.59-$0.35-$0.48 - -$0.13-68.43%Miss-147.2%104 up, 2 downMar 11, 2025$6.28M
    Sep 30, 2024-$0.16-$0.40-$0.65 - -$0.08+60.00%BeatN/A100 up, 0 downNov 12, 2024$24.63M
    Jun 30, 2024-$0.18-$0.40-$0.51 - -$0.22+55.00%BeatN/A100 up, 0 downAug 6, 2024$29.58M
    Mar 31, 2024-$0.20-$0.42-$0.52 - -$0.31+52.38%Beat-106.8%90 up, 0 downMay 13, 2024$19.52M
    Dec 31, 2023$1.25-$0.29-$0.62 - $1.33+531.03%BeatN/A70 up, 0 downFeb 28, 2024$90.06M
    Sep 30, 2023-$0.59-$0.60-$0.68 - -$0.47+1.67%Beat-231.1%70 up, 0 downNov 6, 2023$4.61M
    Jun 30, 2023-$0.51-$0.56-$0.60 - -$0.52+8.93%BeatN/A70 up, 0 downAug 3, 2023$4.85M
    Mar 31, 2023$2.94$1.26-$0.55 - $3.35+133.33%BeatN/A60 up, 0 downMay 9, 2023$150.48M
    Dec 31, 2022-$0.61-$0.55-$0.75 - -$0.38-10.91%Miss-506.7%71 up, 0 downMar 7, 2023N/A
    Sep 30, 2022$0.45-$0.41-$0.56 - $0.44+209.76%BeatN/A70 up, 0 downNov 8, 2022$41.09M
    Jun 30, 2022-$0.50-$0.42N/A-19.05%MissN/AN/A0 up, 0 downAug 4, 2022$712000
    Mar 31, 2022-$0.56-$0.34-$0.69 - $0.64-64.71%MissN/A70 up, 0 downMay 4, 2022$658000
    Dec 31, 2021$0.15-$0.33-$0.72 - $0.17+145.45%BeatN/A90 up, 0 downMar 8, 2022$28.07M
    Sep 30, 2021-$0.67-$0.73-$0.85 - -$0.59+8.22%Beat-129.5%8N/ANov 2, 2021$1.48M
    Jun 30, 2021-$0.80-$0.68-$0.94 - -$0.56-17.65%MissN/A8N/AAug 9, 2021$1.36M
    Mar 31, 2021-$0.58-$0.66-$0.87 - -$0.34+12.12%BeatN/A10N/AMay 10, 2021$6.50M
    Dec 31, 2020-$0.43-$0.57-$1.03 - -$0.07+24.56%BeatN/A12N/AFeb 25, 2021$6.54M
    Sep 30, 2020$2.27$0.20-$0.95 - $2.42N/AN/AN/A12N/ANov 9, 2020$117.84M
    Jun 30, 2020-$0.23-$0.69-$0.92 - -$0.55+66.67%Beat-179.3%11N/AAug 10, 2020$28.68M
    Mar 31, 2020-$0.66-$0.81-$1.13 - -$0.24+18.52%BeatN/A14N/AMay 6, 2020$18.07M
    Dec 31, 2019-$0.34-$0.81-$1.12 - -$0.34+58.02%BeatN/A11N/AMar 3, 2020$32.67M
    Sep 30, 2019-$0.41-$0.67-$1.00 - -$0.49+38.81%BeatN/A10N/ANov 6, 2019$20.43M
    Jun 30, 2019$0.29-$0.80-$0.97 - -$0.48+136.25%BeatN/A11N/AAug 9, 2019$46.09M
    Mar 31, 2019-$0.81$0.58-$0.94 - $4.73-239.66%MissN/A10N/AMay 7, 2019$5.20M
    Dec 31, 2018-$0.70-$0.71-$0.95 - -$0.55+1.41%BeatN/A9N/AFeb 26, 2019$2.01M
    Sep 30, 2018-$0.63-$0.76-$0.94 - -$0.46+17.11%BeatN/A9N/ANov 7, 2018$2.09M
    Jun 30, 2018-$0.80-$0.66-$0.80 - -$0.47-21.21%MissN/A9N/AAug 7, 2018$2.58M
    Mar 31, 2018-$0.63-$0.61-$0.77 - $1.38-3.28%MissN/A9N/AMay 10, 2018$942000
    Dec 31, 2017-$0.40-$0.72-$0.92 - -$0.48+44.44%BeatN/A10N/AMar 14, 2018$6.35M
    Sep 30, 2017-$0.89-$0.71-$0.82 - -$0.48-25.35%MissN/A10N/ANov 2, 2017$1.15M
    Jun 30, 2017-$0.73-$0.59-$0.74 - -$0.48-23.73%MissN/A5N/AAug 8, 2017$1.18M
    Mar 31, 2017-$0.65-$0.53N/A-22.64%MissN/AN/AN/AMay 9, 2017$1.46M
    Dec 31, 2016-$0.57-$0.45N/A-26.67%MissN/AN/AN/AMar 15, 2017$2.36M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.04, after -$1.13 the year before. It was -$1.58 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.04N/A
    Dec 31, 2024-$1.13-136.6%
    Dec 31, 2023$3.09N/A
    Dec 31, 2022-$1.22N/A
    Dec 31, 2021-$1.90-300.0%
    Dec 31, 2020$0.95N/A
    Dec 31, 2019-$1.27N/A
    Dec 31, 2018-$2.76N/A
    Dec 31, 2017-$2.67N/A
    Dec 31, 2016-$1.58N/A

    Earnings Calls

    The 3 most recent earnings calls are listed below; the latest, 2024Q4 for the period ended Dec 31, 2024, runs about 7,300 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q4Dec 31, 20247,28418
    2024Q3Sep 30, 20245,18012
    2024Q2Jun 30, 20245,77214

    2024Q4 Earnings Call

    Opening remarks

    Trista Morrison Chief Corporate Affairs Officer Good afternoon. We issued our fourth quarter and year-end 2024 financial results press release this afternoon. The press release and 10-K are available on our website. On today's call, Dr. Al Sandrock, our Chief Executive Officer, will briefly review key recent and upcoming milestones, and we will reserve most of our time for your Q&A. Joining us for Q&A are Dr. Toby Ferguson, our Chief Medical Officer; Dr. Todd Carter, our Chief Scientific Officer; and Dr. Nathan Jorgensen, our Chief Financial Officer. Before we get started, I would like to remind everyone that during this call, Voyager representatives may make forward-looking statements, as noted in Slide 2 of today's deck. These statements are based on our current expectations and beliefs. They are subject to risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings, which are available on our website for additional detail. Now, I will turn the call over to Al.

    Alfred Sandrock Chief Executive Officer Good afternoon, everyone, and thank you for joining us. As Trista said, we plan to keep our remarks brief and prioritize your questions. On Slide 3, I want to remind you of why we're so excited about Voyager. Our pipeline includes four wholly owned and 13 partnered programs. We have already begun to generate clinical data, and we have multiple opportunities to generate more in the coming years. We are particularly excited about our two wholly owned programs targeting tau, which we view as the most important target in Alzheimer's disease. We also have two platforms to enable CNS delivery. I think most of you are familiar with our TRACER capsid platform for IV-delivered, CNS-targeted gene therapies. We are also generating data with our ALPL-based non-viral shuttle. I am hopeful we will be able to share some of that data with you later this year. Finally, our partnerships have been a significant source of non-dilutive revenue for us. That's the big reason we are able to report $332 million in cash as of the end of 2024. And with $8.2 billion in potential future milestone payments, we believe partnerships will continue to contribute significantly to our bottom line. As I always say, we are open for additional business. We are always discussing new partnership opportunities. While we are building a multimodality neurotherapeutics company here, I want to make a comment about gene therapy, which comprises much of our current pipeline. Despite continued setbacks in the field, it is possible to create a gene therapy that drives value for patients and investors. Zolgensma proves this.

    Frequently Asked Questions About VYGR

    When is Voyager Therapeutics's next earnings date?

    Voyager Therapeutics's next earnings report is expected for Mar 8, 2027.

    Did VYGR beat earnings estimates last quarter?

    Yes. Voyager Therapeutics reported EPS of -$0.40 for the quarter ended Sep 30, 2026, above the -$0.41 estimate, a 2.44% surprise.

    What EPS do analysts expect from VYGR next quarter?

    The consensus EPS estimate for Voyager Therapeutics for the quarter ending Dec 31, 2026 is -$0.42 from 13 analysts, with estimates from -$0.88 to -$0.08.

    How often does VYGR beat earnings estimates?

    Voyager Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -4.99%.